Burger King has appointed Joel Yashinsky as chief marketing officer (CMO) for the US and Canada. Yashinsky's task is to further develop the brand's "Reclaim the Flame" strategy, which has been ...

The little voice in your head is going to keep saying "buy them, buy them" until you finally do, so you might as well silence ...

5. **Using Inefficient Joins** - Improper use of joins (e.g., unnecessary Cartesian joins) can result in slow queries. Ensure you're using the right join type for your data relationship.

Cartesian Therapeutics, Inc.’s RNAC share price has surged by 21.84%, which has investors questioning if this is right time to sell.

Cartesian reports 12-month data for Descartes-08 in myasthenia gravis; Phase 3 AURORA trial expected to begin in Q2 2025.

Deal-making news last week included US drug developer KalVista Pharma signing a licensing agreement with Kaken Pharma to market its investigational hereditary angioedema (HAE) drug sebetralstat in ...

US biotech Cartesian Therapeutics has reported that patients with generalized myasthenia gravis (gMG) continued to experience ...

Venus Concept shares jumped 201% to $8.67 in pre-market trading Here are some other stocks moving in pre-market trading. Femto Technologies Inc. FMTO rose 95.7% to $5.50 in pre-market trading after ...

Mellman, who while at Genentech played a key role in the development of the cancer drug Tecentriq, said the decision to join was cemented by meetings with Parker. He said that he and his ...

Sobi licensed SEL-212 from Selecta Biosciences – now called Cartesian Therapeutics – in June 2020 for $100 million upfront and milestone payments of up to $630 million. It is responsible for ...

Hey there. Today, we talk about the NIH’s database ban on researchers in countries including China and Russia, discuss the legality of the HHS firings, and more. The XBI fell more than 4% ...